GlassScriptPhysician profile
Norman C Pang
NPI 1861434367
$5,494.81
in general payments reported to CMS, 2019-2025
36 companies · $1,309 in 2025
The $1,309 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,518 · 2020: $425 · 2021: $450 · 2022: $704 · 2023: $487 · 2024: $601 · 2025: $1,309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,802 · Travel and Lodging: $596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,801.82 |
| Travel and Lodging | $595.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $1,291.04 | 2019-2025 | Belbuca, Xtampza |
| Si-Bone, INC. | $666.34 | 2024-2025 | |
| Scilex Pharmaceuticals INC. | $572.92 | 2021-2025 | Ztlido |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $483.12 | 2019-2025 | Relistor |
| Electronic Waveform Lab, INC. | $280.98 | 2019-2025 | |
| Abbvie INC. | $197.44 | 2019-2025 | |
| Forte Bio-Pharma LLC | $174.45 | 2022-2025 | Prolate, Nalocet, Tanlor |
| Biodelivery Sciences International, INC. | $163.77 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $133.98 | 2019-2020 | |
| Vertex Pharmaceuticals Incorporated | $129.80 | 2024-2025 | |
| Abbott Laboratories | $126.20 | 2019-2024 | Eterna |
| Indivior INC. | $125.40 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $111.08 | 2022-2023 | Seglentis |
| Eisai INC. | $108.40 | 2020-2021 | |
| Mdd US Operations, LLC | $107.15 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $92.59 | 2019-2021 | |
| Daiichi Sankyo INC. | $80.50 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $68.90 | 2024 | Dysport |
| Assertio Therapeutics, INC. | $64.67 | 2019 | |
| Kaleo, INC. | $62.54 | 2019 | |
| Nevro Corp. | $59.24 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $47.13 | 2022-2023 | Belsomra |
| Hikma Pharmaceuticals USA | $46.83 | 2022 | |
| Stryker Corporation | $41.91 | 2019 | |
| Relievant Medsystems, INC. | $33.23 | 2023 | Intracept |
| Redhill Biopharma INC. | $32.71 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $27.07 | 2021 | |
| Zyla Life Sciences, INC. | $21.40 | 2019 | |
| Orexo US, INC. | $21.23 | 2020 | |
| Medtronic USA, INC. | $20.94 | 2019 | |
| Virtus Pharmaceuticals LLC | $20.41 | 2025 | Levorphanol Tartrate |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.80 | 2019 | |
| Azurity Pharmaceuticals, INC. | $18.70 | 2023 | Horizant |
| Arbor Pharmaceuticals, INC. | $15.79 | 2019 | |
| Shionogi INC | $15.05 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman Pang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.